Requires insurers to cover the substitution of a brand name prescription drug when the federal food and drug administration has declared that there is a supply issue with a generic drug.
- Chamber
- House
- Introduced
- Jan 9, 2025
- Last action
- Jun 1, 2026 — RETURNED TO ASSEMBLY
- Session
- 2025-2026
- Momentum
- 61 · High